Angelo Michael De Marzo

The paper identifies a WIF1+ basal cell subtype enriched in the transition zone of the prostate and links it to benign prostatic hyperplasia through molecular and pathway analyses.

The paper uses spatial multi-omics and single-cell transcriptomics to identify senescence-associated programs in colon adenoma to cancer progression, finding GDF15 mediates senescence-stemness coupling and immune exclusion.

This paper identifies triptolide as a compound that enhances the effectiveness of DNMTi by inhibiting DCTPP1, overcoming resistance in cancer cells.

The paper examines subclonal complete loss of CDKN1B in prostate cancer, finding higher prevalence in African American individuals and associations with worse outcomes.

This study shows that loss of miR-21 in MYC-driven prostate cancer reduces tumor progression by affecting cell-type-specific gene regulation and immune infiltration.

SVCFit estimates SV cellular fractions from bulk sequencing to reconstruct clonal evolution in mCRPC under therapy, showing treatment-driven clonal reconfiguration.

The paper identifies RPL22 as a splicing regulator linking rRNA synthesis to mRNA splicing, showing that Pol I inhibition reverses RPL22-dependent alternative splicing.

This paper identifies hydroxyflutamide as an AR arrested agonist that induces DNA damage in prostate cancer cells, enabling selective radiosensitization without promoting growth.

This study identifies MYC signaling activation as a common driver of tumor microenvironment alterations in human and murine prostate cancer through single-cell RNA-sequencing and comparative analysis.